Navigation Links
Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R)
Date:9/19/2011

PARSIPPANY, N.J., Sept. 19, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths.  Enoxaparin Sodium Injection is the generic equivalent to Sanofi-aventis' LOVENOX®, and is a low molecular weight heparin indicated in the prophylaxis and treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction.  

Pursuant to the terms of the parties' exclusive Distribution Agreement, Amphastar will supply Enoxaparin Sodium Injection to Watson, which will market, sell and distribute the product to the U.S. retail pharmacy channel.  Amphastar will receive between 50 and 55 percent of Watson's gross profits on product sales, depending on the number of competitors in the market.  Amphastar will market, sell and distribute the product to all other channels.  For the 12-months ending July 30, 2011, LOVENOX® and its generic equivalents had total U.S. sales of approximately $2.6 billion, according to IMS Health.  Amphastar is currently preparing for launch and anticipates launching its Enoxaparin Sodium Injection product in the fourth quarter of 2011.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc., established in 1996, is a specialty and generic pharmaceutical company focusing on injectable, inhalation, and other categories of pharmaceutical products. Amphastar's state-of-the-art, aseptic, cGMP compliant facilities develop, manufacture, and market innovative proprietary and generic products using new technologies and delivery systems.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended June 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LOVENOX® is a registered trademark of Sanofi-aventis U.S. LLC.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
2. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
3. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
4. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
5. Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
6. Watson Confirms JALYN™ Patent Challenge
7. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
8. Watson Confirms Vyvanse® Patent Challenge
9. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings
10. Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility
11. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 /PRNewswire/ ...  a leading organization within medical affairs in the ... as the chair of a newly formed ... additional board members to form the first ever ... For more information about the ACMA, ...
(Date:3/24/2017)... March 24, 2017 FinancialBuzz.com News Commentary  ... According ... of cannabis market research, the legal cannabis market is projected ... 2021, despite conflicting signals from the current presidential administration. The ... the two biggest drivers of growth in this industry are ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in ... and leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance ... is designed to teach how to maximize their sales efforts, as well as ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... stories about real people of God in congregations across the United States. ... Presbyterian minister ordained in 1964 who has served congregations in seven states throughout ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... services to their communities, 16 more public health departments have been awarded national ... bring another 4.5 million people into the expanding network of communities across the ...
(Date:3/23/2017)... ... 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play ... the minimum two times a day that dentists recommend. The ramifications of improper oral upkeep ... school and adults missing 164 million hours of work each year due to dental issues. ...
Breaking Medicine News(10 mins):